The effect of prior exposure to imatinib on transplant-related mortality.

Abstract

Within the limits of a heterogeneous and relatively small cohort of patients, we found no evidence that imatinib negatively affects major outcomes after SCT, suggesting that imatinib prior to SCT is safe.